QSP

(M-005) Coupling A Quantitative Systems Pharmacology Model With A Simple Statistical Layer To Predict Asthma Exacerbation Rate Reduction From Allergen Challenge Results

(M-006) An innovative paradigm for non-small cell lung cancer clinical trial simulations through the Integration of a quantitative systemic pharmacology model and pharmacodynamic model of gemcitabine

(M-007) Leveraging AI for improved reproducibility of mathematical disease models: insights from a retinitis pigmentosa case study

(M-008) A within-host dynamic model of Bordetella pertussis to support vaccine development

(M-010) Quantitative system pharmacology model for tri-specific HER2xCD3xCD28 T-Cell Engager SAR443216

(M-013) Development of a quantitative systems pharmacology model for Hepatitis B Virus infection and Hepatitis D virus co-infection.

(M-020) Dissecting Bcl-2 Sensitivity In Acute Myeloid Leukemia: A Quantitative Systems Pharmacology Model For Venetoclax-Azacitidine Therapy

(M-021) Towards A Computational QSP Platform To Support Antibody Drug Conjugate Design In Cancer

(M-022) Towards A QSP Platform To Support Drug Development In Hematological Cancers

(M-024) Mechanistic Translational Modeling Versus Minimal Anticipated Biological Effect Level Approach to Predict First-in-human Dose For T-cell Engagers: HPN536 Case Study.

(M-025) A quantitative systems pharmacology (QSP) model to enable prediction of ARIA-E incidence with anti-Aβ monoclonal antibody therapies for Alzheimer’s disease

(M-030) A Minimal QSP Model for Treg Responses of IL-2 Mutein MK-6194 – A Conceptual Model for Autoimmune Disease

(M-044) MIDD Platform of VZV Vaccine Immunogenicity and Efficacy

(M-054) Preclinical data exposures underpredict clinical physiologically active doses for bispecific TCEs in solid tumors indications; are there better metrics? - insights from a small mechanistic MBMA

(M-056) A Translational Quantitative Systems Pharmacology (QSP) Modeling Framework to Predict Interleukin-15 (IL-15) Cytokine Levels in Multiple Myeloma Patients after Anti-BCMA CAR-NK Cell Therapy

(M-065) Decoding Mean Viral Load in RSV Human Challenge Studies

(M-066) Optimizing Clinical Translation of Bispecific T Cell Engagers through Context Unification with a Quantitative Systems Pharmacology Model

(M-068) A translational QSP model to characterize the preclinical pharmacodynamics of combining a KRAS G12C inhibitor with a SHP2 inhibitor

(M-072) A shared pool modeling approach to describe antibody-mediated cell-cell interactions

(M-073) A Scalable Cloud-Based QSP Modeling System for Virtual Patient Generation

(M-078) PKPD Modeling of PROTACs

(M-085) PBPK-mQSP Model Analysis of KHK4951, an Eye Drop Formulation of Tivozanib, a Potent and Selective VEGF Receptor Inhibitor

(M-092) Integrated Quantitative Systems Pharmacology and Pharmacometric Model to Evaluate Effective Buprenorphine Induction Treatment Strategies in the Era of Synthetic Opioids

(M-100) A Quantitative Systems Pharmacology Model of LNP-mRNA Uptake Through LDLR Binding

(M-101) Cardiovascular Model Parameterization of Digital Twins for Acute Care Drug Delivery: An Iterative Bayesian Approach

(M-105) Sex differences in patients with chronic kidney disease: A quantitative systems pharmacology modeling study

(M-109) Advancing Quantitative Systems Pharmacology Model for Inflammatory Bowel Disease for Clinical Efficacy Predictions in Ulcerative Colitis

(M-110) A quantitative systems pharmacology model for diabetes-induced glomerular fibrosis

(M-114) Virtual clinical trial simulations using a Quantitative Systems Pharmacology (QSP) model of CDK inhibitors in breast cancer patients

(M-120) Quantitative Systems Toxicology Modeling of Otenaproxesul Liver Enzyme Elevations Leads to Prediction of Liver Safety for Acute Otenaproxesul Dosing

(M-127) Creating Cell-specific Computational Models of Stem Cell-derived Cardiomyocytes Using Optical Experiments

(T-002) Representation of antibodies is key to generate a predictive vaccine quantitative systems pharmacology (QSP) model

(T-008) Quantitative Systems Pharmacology (QSP) model for combined targeting of BAFF and CD40 pathways in systemic lupus erythematosus

(T-009) Development of QSP platform model for predicting clinical efficacy and CRS incidence of CD3 bispecifics in STEAP1 Prostate Cancer

(T-010) A quantitative systems pharmacology model framework for combined clinical efficacy and hematological toxicity predictions for antibody drug conjugates

(T-013) A hybrid semi-mechanistic and machine learning framework to predict Cytokine Release Syndrome following T-cell engaging immunotherapies

(T-015) A quantitative systems pharmacology model to explore resistance mechanisms and combination strategies in ALK+ NSCLC targeted therapies

(T-018) A Neuro-Dynamic Quantitative Systems Pharmacology (QSP) Model to Describe Pathophysiology of Alzheimer’s Disease and Inform Drug Development

(T-030) Integration of Temporal Single-Cell RNA Sequencing Data into Quantitative Systems Pharmacology Model of T Cell Differentiation

(T-031) Comparison of Sensitivity Analysis Methods in the Context of a QSP Model for Gout

(T-034) Translational modeling identifies synergistic combinations of anti-microRNA-155 with standard-of-care drugs in non-small-cell lung cancer

(T-035) Identifying Determinants of Vaccine Efficacy: A Mechanistic Modeling Approach

(T-044) A translational quantitative systems pharmacology modeling framework for FcRn antagonist therapy for myasthenia gravis

(T-061) Impact of PD-L2 on Relative Efficacy of Anti-PD-1 and Anti-PD-L1 Antibodies: Insights From QSP-Based Meta-Analysis

(T-065) Weight Loss and Nausea from Subcutaneous and Oral Semaglutide Accurately Simulated with a QSP Model

(T-067) A quantitative systems pharmacology-physiologically based pharmacokinetic model-guided antibiotics regimen design for the treatment of sepsis and septic shock patients

(T-073) Bispecific T-cell engagers and cytokine release syndrome: Modeling molecule, indication and patient-specific aspects

(T-074) Risk Assessment for Drug-Induced Hyperbilirubinemia: A Mechanistic Approach

(T-079) A mechanistic QSP model of CRS allows for quantitative assessment of dose priming of CD3 bispecific antibody (BsAb) therapeutics.

(T-083) Application of quantitative systems pharmacology modeling in reverse translation

(T-085) Modeling progression and treatment of mCRPC using the Thales QSP software platform

(T-088) A Computational Modeling Framework to Provide a Feasibility Assessment, Inform Competitor Differentiation Strategy, Best-in-Class Properties, and Target Selection for Biologics Targeting IBD

(T-095) Modeling the Role of Organ Crosstalk and Cellular Adaptation in Multiple Organ Dysfunction Syndrome

(T-096) Integrating Motor Function Scores of Spinal Muscular Atrophy in a Quantitative Systems Pharmacology Model of Neurofilament

(T-100) Beyond Subcutaneous Dosing: Efficiency of liver-targeting siRNAs dosed via alternates routes and formulations.

(T-101) A QSP model of atopic dermatitis to accelerate the clinical translation of novel combination therapies

(T-104) Adaptation of the Glucose, Glucagon, Gastric-Inhibitory Peptide, Glucagon-like Peptide-1, and Insulin (4GI) Model for Simulation of Acute Meal Challenges with Infused Antagonists

(T-105) Generating data-driven insights from the Alzheimer’s Disease Neuroimaging Initiative (ADNI): Towards establishing a QSP model of Alzheimer’s disease

(T-106) Simulated CD8+ T Cell-Mediated Liver Injury During Ipilimumab Administration in a Simulated Population (SimPops®) Demonstrates Profiles Consistent with Observed Clinical Data

(T-107) Comprehensive Human Quantitative Systems Pharmacology Models for Immuno-Oncology: Enhancing Decision-Making on Target Indications and Combination Strategies for New Drug Development

(T-113) QSP model trained on preclinical data informs clinical dose selection for a T-cell engaging bispecific antibody for solid tumor indications

(T-115) Approaches for Developing a Robust Virtual Twin Workflow in Quantitative Systems Pharmacology Models

(T-122) A Quantitative Systems Pharmacology Approach to Understand the Variability of Patient Response to T-cell Bi-specifics in Hematological Malignancies

(T-129) A prototype mechanistic systems pharmacology model of Type 2 interventions in eosinophilic esophagitis

(W-001) Leveraging quantitative systems pharmacology (QSP) modeling to understand effects of corticosteroids on immune cells and cytokine release following administration of SC Epcoritamab

(W-004) Development of QSP model of non-small cell lung cancer and its application to support optimal dose selection for acasunlimab, a bispecific antibody targeting 4-1BB and PD-L1

(W-006) Application of identifiability analysis to obtain reliable parameters of the QSP model describing mechanism of action GEN1042 (BNT312) and acasunlimab

(W-010) Modeling the evolution of activation marker distributions in flow cytometry data representing cell populations in patients dosed with immunomodulating agents

(W-015) Eculizumab as a Key Comparator for the Evaluation of Complement Targeted Novel Therapeutic Strategies with a QSP Model

(W-017) Integrating mathematical modeling with multiplexed immunofluorescence data to predict drug-induced cell arrest

(W-018) Novel computational workflow for selecting virtual patient cohorts for in silico clinical trials

(W-033) Adaptation of a Published Kidney Disease QSP Model to Represent Autosomal-Dominant Polycystic Kidney Disease and Evaluate Treatment Options

(W-034) Parallel Tempering for Generation of Virtual Patients and Virtual Populations

(W-035) Systems model to predict fractional exhaled nitric oxide response to inhaled JAK inhibitors in patients with mild to moderate asthma

(W-058) QSP-based virtual twin approach provides mechanistic insight into enzyme replacement therapies in Pompe Disease

(W-059) Facilitating RP2D decisions for CAR T cell therapy clinical studies using a QSP model

(W-060) Quantitative systems pharmacology model for distinguishing efficacy of anti-CD20 therapy variants in populations of Multiple Sclerosis patients

(W-061) Quantitative systems pharmacology modeling of neurotoxicity and cognitive scores in Alzheimer’s disease for prediction of therapy outcomes

(W-063) Cell-line Specific Network Modeling to Assess Differential Signal Transduction of Oxaliplatin-based Drug Combinations for Colorectal Cancer

(W-071) Mathematical modeling can help to successfully translate preclinical findings in mice models of asthma into first-in-human trials

(W-092) Incorporating Computational Fluid Dynamic Modeling into Pharmacometrics Models for Applications to Gene Therapy, Anti-Inflammatory Treatments and Transdermal Patch Drug Delivery

(W-096) Quantitative Systems Pharmacology of T-cell Engagers and Cytokine Release

(W-098) Role of quantitative systems pharmacology (QSP) in optimizing elranatamab dosing regimen for relapsed/refractory multiple myeloma

(W-102) Mathematical optimization of a thrombopoiesis quantitative systems pharmacology (QSP) model

(W-107) Mechanistic Modeling Of Surface Molecule Interactions: Impact Of Methodology On CAR-T Cell Dose Predictions

(W-109) Comparative Analysis of Minimal Physiologically Based Pharmacokinetic (mPBPK) and Traditional Pharmacokinetic (PK) Models in the Context of Quantitative Systems Pharmacology (QSP) for T-cell Engagers

(W-120) Quantitative Systems Pharmacology Modeling of X-linked Hypophosphatemia Disease Pathway Normalization to Predict the Impact of Burosumab Treatment on Serum Biomarkers in Adult and Pediatric Patients

(W-131) Mechanistic modeling to inform T cell engager development for low copy targets

(W-138) A model-based framework for assessing schedule dependence of therapeutic window for three-drug combinations